GlassScriptPhysician profile
Mincha G Parker
NPI 1407820020
$7,877.55
in general payments reported to CMS, 2019-2025
39 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 98% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,268 · 2022: $1,162 · 2023: $1,901 · 2024: $1,859 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,328 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,328.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.44 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $719.53 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $427.32 | 2021-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $395.31 | 2022-2025 | Keytruda |
| Genzyme Corporation | $372.46 | 2021-2024 | |
| Gilead Sciences, INC. | $329.71 | 2022-2024 | Epclusa |
| Glaxosmithkline, LLC. | $293.96 | 2023-2025 | Jemperli |
| Genentech USA, INC. | $262.95 | 2021-2023 | Polivy, Lunsumio |
| Evoke Pharma, INC. | $226.96 | 2023-2024 | Gimoti |
| Daiichi Sankyo INC. | $226.75 | 2022 | |
| Astellas Pharma US INC | $216.22 | 2024 | Cresemba, Veozah |
| Jazz Pharmaceuticals INC. | $210.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $210.11 | 2023-2024 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $209.32 | 2024-2025 | Gemtesa, Myfembree |
| Novo Nordisk INC | $200.29 | 2022-2025 | Wegovy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $182.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.30 | 2021 | |
| Angiodynamics, INC. | $160.88 | 2023 | Nanoknife |
| Janssen Biotech, INC. | $158.63 | 2024 | Darzalex, Tecvayli |
| Gynesonics, INC. | $140.46 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exelixis INC. | $126.14 | 2025 | Cabometyx |
| Abbott Laboratories | $121.85 | 2025 | Freestyle Libre 3 |
| Sobi, INC | $120.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $119.00 | 2024 | Invega Sustenna |
| Insulet Corporation | $116.62 | 2025 | Omnipod |
| G1 Therapeutics, INC. | $116.44 | 2021 | |
| Axsome Therapeutics, INC. | $109.62 | 2023 | Auvelity |
| Amgen INC. | $107.39 | 2025 | Imdelltra (Amg757) |
| Kyowa Kirin, INC. | $107.39 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $100.49 | 2023 | Crysvita |
| Paratek Pharmaceuticals, INC. | $100.49 | 2022 | |
| Kci USA, INC. | $99.55 | 2023 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Mirati Therapeutics, INC. | $98.68 | 2023 | Krazati |
| Mayne Pharma Commercial LLC | $95.69 | 2024 | |
| Neurelis, INC. | $93.00 | 2025 | Valtoco |
| Lilly USA, LLC | $86.18 | 2023 | Verzenio |
| Idorsia Pharmaceuticals US INC | $79.65 | 2023 | Quviviq |
| Eisai INC. | $70.81 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mincha Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.